Whittier Trust Co. of Nevada Inc. Has $24.72 Million Stake in Johnson & Johnson $JNJ

Whittier Trust Co. of Nevada Inc. cut its holdings in Johnson & Johnson (NYSE:JNJ) by 3.1% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 131,064 shares of the company’s stock after selling 4,192 shares during the quarter. Whittier Trust Co. of Nevada Inc.’s holdings in Johnson & Johnson were worth $24,724,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of the stock. Clark Asset Management LLC grew its holdings in Johnson & Johnson by 51.6% during the 2nd quarter. Clark Asset Management LLC now owns 8,884 shares of the company’s stock valued at $1,357,000 after buying an additional 3,025 shares in the last quarter. Treasurer of the State of North Carolina increased its holdings in Johnson & Johnson by 8.3% during the 2nd quarter. Treasurer of the State of North Carolina now owns 1,234,945 shares of the company’s stock worth $188,638,000 after acquiring an additional 94,957 shares during the period. Talbot Financial LLC boosted its holdings in Johnson & Johnson by 4.6% in the 3rd quarter. Talbot Financial LLC now owns 138,424 shares of the company’s stock valued at $25,667,000 after purchasing an additional 6,143 shares during the period. Liberty One Investment Management LLC increased its holdings in shares of Johnson & Johnson by 83.9% in the third quarter. Liberty One Investment Management LLC now owns 366,813 shares of the company’s stock worth $68,040,000 after purchasing an additional 167,353 shares during the period. Finally, Winnow Wealth LLC bought a new stake in Johnson & Johnson during the second quarter valued at $295,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Key Stories Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: FDA approved a DARZALEX FASPRO®-based quadruplet regimen (D-VRd) for newly diagnosed, transplant‑ineligible multiple myeloma patients — expands DARZALEX’s label into another front‑line setting and could drive meaningful incremental biologics revenue over coming years. DARZALEX FASPRO® approval
• Positive Sentiment: Company set 2026 guidance above Street expectations and reiterated aggressive growth targets (JNJ is targeting $100B+ sales in 2026), supporting revenue upside and investor confidence in the medium term. J&J Targets $100B+ Sales in 2026
• Positive Sentiment: Analysts are turning more bullish: TipRanks notes rising analyst optimism and Guggenheim raised its price target to $240 after solid Q4 and the 2026 guide — analyst upgrades and higher PTs can help sustain buying momentum. TipRanks bullish trend Guggenheim lifts outlook
• Neutral Sentiment: Unusual options activity — traders bought ~37,990 calls (a ~23% rise vs typical daily call volume) which can amplify intraday moves but doesn’t guarantee sustained directional change. (Options volume report)
• Neutral Sentiment: Multiple investor‑oriented writeups (Zacks, other outlets) highlight JNJ as a strong momentum/dividend name — supports retail interest but is commentary rather than new fundamental news. Zacks momentum piece
• Neutral Sentiment: Corporate philanthropy: J&J marked $100M of MedTech donations since 2020 — positive for ESG profile but limited direct impact on near‑term earnings. MedTech donations
• Negative Sentiment: Headline risk from policy and cost pressures — coverage notes that rising policy costs could weigh on profitability despite strong guidance; keep an eye on regulatory/payer dynamics that could cap margin expansion. Policy costs loom

Johnson & Johnson Trading Up 1.1%

Shares of JNJ stock traded up $2.38 during mid-day trading on Wednesday, reaching $226.82. The stock had a trading volume of 974,119 shares, compared to its average volume of 8,993,431. The company has a current ratio of 1.07, a quick ratio of 0.80 and a debt-to-equity ratio of 0.50. The stock’s 50-day moving average price is $209.28 and its two-hundred day moving average price is $190.32. The firm has a market capitalization of $546.47 billion, a PE ratio of 20.51, a price-to-earnings-growth ratio of 2.15 and a beta of 0.34. Johnson & Johnson has a 52-week low of $141.50 and a 52-week high of $228.42.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Wednesday, January 21st. The company reported $2.46 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $2.46. The company had revenue of $24.56 billion for the quarter, compared to the consensus estimate of $24.14 billion. Johnson & Johnson had a return on equity of 33.34% and a net margin of 28.46%.Johnson & Johnson’s revenue was up 9.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.04 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.430-11.630 EPS. Equities analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Tuesday, February 24th will be given a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 2.3%. The ex-dividend date of this dividend is Tuesday, February 24th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 47.06%.

Analysts Set New Price Targets

A number of brokerages recently weighed in on JNJ. Argus raised their target price on shares of Johnson & Johnson from $210.00 to $240.00 in a research note on Friday, January 23rd. Morgan Stanley set a $262.00 target price on Johnson & Johnson and gave the company an “overweight” rating in a research note on Wednesday. Guggenheim upped their price objective on Johnson & Johnson from $227.00 to $240.00 and gave the stock a “buy” rating in a report on Friday. The Goldman Sachs Group reissued a “buy” rating and set a $250.00 price objective on shares of Johnson & Johnson in a report on Thursday, January 22nd. Finally, Citigroup increased their price target on shares of Johnson & Johnson from $232.00 to $250.00 and gave the company a “buy” rating in a research report on Thursday, January 22nd. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and eight have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Johnson & Johnson presently has an average rating of “Moderate Buy” and an average price target of $230.36.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.